MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Oncogenic RAS proteins elevate reactive oxygen species (ROS), which paradoxically promote malignancy while also triggering tumor suppression.
• RAS-driven cancer cells necessitate robust redox-protective mechanisms to counteract ROS-induced damage.
• MutT Homolog 1 (MTH1), an 8-oxodGTPase, plays a key role in mitigating oxidative damage within the nucleotide pool.

Purpose of the Study:

• To investigate the role of MTH1 in maintaining pro-malignant traits driven by KRAS mutations in non-small cell lung carcinoma (NSCLC).
• To elucidate the molecular mechanisms by which MTH1 influences KRAS-driven oncogenesis and tumor progression.

Main Methods:

• Utilized a non-small cell lung carcinoma (NSCLC) model with KRAS mutations.
• Performed MTH1 suppression experiments in KRAS-mutant NSCLC cells and immortalized lung epithelial cells.
• Analyzed MTH1 expression in human NSCLC tumors and correlated it with KRAS levels.
• Investigated the impact of MTH1 loss on DNA damage, senescence, proliferation, and KRAS expression in p53-competent and p53-nonfunctional cells.

Main Results:

• MTH1 suppression impaired proliferation and xenograft tumor formation in KRAS-mutant NSCLC cells.
• MTH1 levels were found to modulate KRAS-induced cellular transformation.
• MTH1 expression was upregulated by oncogenic KRAS and positively correlated with KRAS levels in human NSCLC.
• In p53-competent cells, MTH1 loss induced DNA damage and senescence; in p53-nonfunctional cells, it reduced proliferation and KRAS expression.

Conclusions:

• MTH1 is essential for sustaining KRAS-driven pro-malignant phenotypes in NSCLC.
• MTH1 functions not only in preventing oxidative DNA damage but also in regulating oncogene expression levels.
• MTH1 represents a critical component in KRAS-associated malignancy, suggesting its inhibition as a potential therapeutic strategy for KRAS-driven tumors.